<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162341</url>
  </required_header>
  <id_info>
    <org_study_id>RC-P0056</org_study_id>
    <nct_id>NCT03162341</nct_id>
  </id_info>
  <brief_title>Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit</brief_title>
  <acronym>GOUT-DECTUS</acronym>
  <official_title>Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit in Urate Lowering Therapy Initiators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Horizon Pharma Rheumatology LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this research is to evaluate the correlation between DECT and US
      explorations performed in a routine clinical setting for the measurement of change in tophus
      size in gout patients after 24 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between US and DECT measurement of change in tophus volume</measure>
    <time_frame>after 24 months of treatment</time_frame>
    <description>Spearman rank correlation between the change in tophus volume after 24 months of treatment measured by ultrasonography or by DECT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between US and DECT measurement of change in tophus volume</measure>
    <time_frame>after 6 months, 12 months and 24 months of treatment</time_frame>
    <description>Spearman rank correlation between the change in tophus volume after 6, 12 and 24 months of treatment measured by ultrasonography or by DECT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of DECT urate score</measure>
    <time_frame>after 6 months, 12 months and 24 months of treatment</time_frame>
    <description>Change from baseline after 6, 12 and 24 months of treatment in DECT urate score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Link between the change of DECT urate score and the persistence of the double contour sign</measure>
    <time_frame>after 6 months, 12 months and 24 months of treatment</time_frame>
    <description>During ultrasonography, a double contour of the articulation can be visible. This outcome will compare the change in the DECT urate score between the patients for who the double contour stay visible and those for who it disapear.
This outcome register if this double contour stay visible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the change of DECT urate score and the change in serum uric acid levels</measure>
    <time_frame>after 6 months, 12 months and 24 months of treatment</time_frame>
    <description>The Spearman correlation between the change from baseline of the DECT urate score and the serum uric acid levels will be computed for each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the change of DECT urate score and the number of gout attacks</measure>
    <time_frame>after 6 months, 12 months and 24 months of treatment</time_frame>
    <description>The Spearman correlation between the change from baseline of the DECT urate score and the number of gout attack will be computed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>UltraSonography and DECT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UltraSonography and DECT will be used in patient monitoring after 6, 12 and 24 months of treatment in order to evaluate the correlation between the 2 explorations for the measurement in tophus volume change.
Those are interventions that are not part of the standard care of the patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasonography</intervention_name>
    <description>The tophus volume will be assess using ultrasonography.</description>
    <arm_group_label>UltraSonography and DECT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DECT</intervention_name>
    <description>The tophus volume will be assess using dual-energy computed tomography (DECT).</description>
    <arm_group_label>UltraSonography and DECT</arm_group_label>
    <other_name>dual-energy computed tomography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of gout based on the ACR/EULAR 2015 criteria

          -  uricemia ≥6 mg/dL

          -  warranted introduction of urate-lowering therapy according to the ACR 2012 or EULAR
             2016 criteria

          -  signature of the informed consent

          -  social insurance affiliation

        Exclusion Criteria:

          -  pregnancy or breastfeeding

          -  patient under legal guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tristan Pascart, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Group of the Catholic Institute of Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sébastien Ottaviani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bichat Hospital of Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal Richette, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lariboisiere Hospital of Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie Lansiaux, MD PhD</last_name>
    <phone>+33320225269</phone>
    <email>lansiaux.amelie@ghicl.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélody Plets, CRA</last_name>
    <phone>+33320225733</phone>
    <email>plets.melody@ghicl.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Group of the Catholic Institute</name>
      <address>
        <city>Lomme</city>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie Lansaux, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tristan Pascart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien Ottaviani, MD</last_name>
      <email>sebastien.ottaviani@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lariboisière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Richette, MD PhD</last_name>
      <email>pascal.richette@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dual-Energy Computed Tomography</keyword>
  <keyword>UltraSonography</keyword>
  <keyword>Gout</keyword>
  <keyword>Urate deposition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

